Partial
Mostly Aligned
Patient Risk:
Low
Summary
Only the statement that gabapentin is the active ingredient in NEURONTIN is supported by the provided label excerpts. Most claims about brand products (Gralise, Horizant), extended-release characteristics, dosing/prescription-type differences, and clinician choice are not supported by the supplied label sections.
Category Scores
Accurate Statements
Gabapentin’s generic name is gabapentin.
11 DESCRIPTION (active ingredient in NEURONTIN is gabapentin).
Unsupported Statements
Brand-name versions of gabapentin include Gralise.
Not supported by the provided label excerpts.
Brand-name versions of gabapentin include Horizant.
Not supported by the provided label excerpts.
Gabapentin is widely available as a generic medication under the name gabapentin.
The provided label identifies gabapentin as the active ingredient but does not address generic availability or market prevalence.
Brand-name gabapentin products exist.
Existence of specific brand products is not stated in the provided label excerpts.
Brand-name gabapentin products are tied to particular formulations.
The provided excerpts do not state that brand-name gabapentin products are tied to particular formulations (beyond listing NEURONTIN dosage forms).
Brand-name gabapentin products are tied to particular indications.
While NEURONTIN indications are provided, the claim is framed generally about brand-name gabapentin products; the label excerpt does not support this generalization.
Brand products such as Gralise and Horizant are formulated as extended-release gabapentin products.
No information about these specific products or extended-release formulations is present in the provided label excerpts.
Extended-release gabapentin products affect dosing schedules.
The provided label excerpts do not describe dosing-schedule differences for extended-release products.
Extended-release gabapentin products affect the type of prescription compared with many standard generic gabapentin products.
No statement in the provided label excerpts supports differences in prescription type.
Which gabapentin product is appropriate depends on the prescribing clinician’s choice.
The provided label excerpt does not discuss product selection based on clinician choice.
Contradictions
Important Omissions
No evaluation of contraindications, boxed warnings, drug interactions, adverse reactions, monitoring, administration instructions, or storage/handling can be performed because the underlying AI response content beyond the listed claims is not provided and only limited label sections (Indications/Usage, Description, Dosage Forms/Strengths) were supplied.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only supported label claim among the provided excerpts concerns the active ingredient name. The other claims are primarily about brand/product naming and formulation characteristics; the supplied excerpts do not link these statements to specific contraindications, warnings, dosing, or safety requirements, so direct label-based safety inconsistency cannot be determined from the provided information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple brand-specific and formulation-specific claims (Gralise, Horizant, extended-release effects, dosing/prescription-type differences, clinician choice) are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to label-supported content from the provided excerpts (e.g., NEURONTIN indications and that gabapentin is the active ingredient; if discussing other products or extended-release characteristics, provide corresponding FDA label citations for those specific products).